Rebel Medicine
Rebel Medicine is a science-led pharmaceutical company dedicated to revolutionizing acute pain management by developing innovative, non-opioid solutions. Their mission is to create impactful products that improve patient outcomes and reduce healthcare costs. By leveraging novel drug delivery technologies, Rebel Medicine aims to provide effective pain management solutions that eliminate the need for opioids, thus addressing a significant unmet medical need in acute and postoperative pain management.
Industries
Nr. of Employees
small (1-50)
Rebel Medicine
48 S Rio Grande Street, Salt Lake City, UT 84101
Patents
Products
Alevatrix
An injectable, extended-release gel formulation of a local anesthetic intended to provide multi-day postoperative analgesia via infiltration or peripheral nerve block; designed for prefilled syringe presentation.
ALX-UL
An ultra long-acting injectable formulation designed to extend local analgesia to approximately 7 days using the same injectable drug-delivery form factor as other gel candidates.
RBL-001
An extended-release solution formulation of a local anesthetic intended for quick onset and 36–48 hours of analgesia for surgical, dental, obstetrical, and diagnostic/therapeutic procedures.
Alevaderm
A composite, drug-releasing wound dressing under development to provide up to 7 days of localized analgesia while supporting moist wound-healing and minimizing dressing changes.
Alevatrix
An injectable, extended-release gel formulation of a local anesthetic intended to provide multi-day postoperative analgesia via infiltration or peripheral nerve block; designed for prefilled syringe presentation.
ALX-UL
An ultra long-acting injectable formulation designed to extend local analgesia to approximately 7 days using the same injectable drug-delivery form factor as other gel candidates.
RBL-001
An extended-release solution formulation of a local anesthetic intended for quick onset and 36–48 hours of analgesia for surgical, dental, obstetrical, and diagnostic/therapeutic procedures.
Alevaderm
A composite, drug-releasing wound dressing under development to provide up to 7 days of localized analgesia while supporting moist wound-healing and minimizing dressing changes.
Expertise Areas
- Loco-regional anesthesia drug development
- Extended-release local anesthetic formulation
- Drug-eluting wound dressing development
- Preclinical pharmacology and large-animal efficacy studies
Key Technologies
- Sustained-release injectable hydrogel delivery systems
- Drug-eluting composite wound dressings
- Prefilled syringe drug formulations
- Tunable multi-day release kinetics
Key People
News & Updates
Rebel Medicine has successfully completed a Pre-IND meeting for their lead asset, Alevatrix™, marking a significant milestone in its development.
The company has published data from pre-clinical studies of Alevatrix™ in large animals, demonstrating its efficacy in pain management.
Rebel Medicine has been awarded significant grants from NSF and NIH to further their research and development efforts.
Rebel Medicine has successfully completed a Pre-IND meeting for their lead asset, Alevatrix™, marking a significant milestone in its development.
The company has published data from pre-clinical studies of Alevatrix™ in large animals, demonstrating its efficacy in pain management.
Rebel Medicine has been awarded significant grants from NSF and NIH to further their research and development efforts.